ÂÜÀòÂÒÂ×

Mr. Oliveto has served as Milestone’s President and Chief Executive Officer since March 2017 and as a member of Milestone’s board of directors since July 2017. Prior to Milestone Pharmaceuticals, Mr. Oliveto was President, CEO, and Director of Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) where he led the company through a successful turnaround that included an NDA filing for, and FDA approval of, Northera™, a drug for the treatment of Neurogenic Orthostatic Hypotension, and the subsequent sale of Chelsea to Lundbeck, Inc. Mr. Oliveto joined Chelsea in 2008 following a two-year assignment as an Executive in Residence at Pappas Ventures, a life sciences venture capital firm, where he advised portfolio companies on strategy and governance. Prior to Pappas Ventures, Mr. Oliveto served in a number of progressively senior positions across several operating areas over an 18-year career at Hoffmann-La Roche Inc., including as a Global Alliance Director for Roche’s partnering organization. During his tenure, he played an integral part in the success of multiple NDA approvals, comprehensive launch programs, and licensing transactions.

Mr. Oliveto received a BA in Chemistry and an MBA from Rutgers University.